FDA Grants Accelerated Approval for INOVIO's Voceryq to Treat Recurrent Respiratory Papillomatosis

The FDA has granted accelerated approval to INOVIO's immunotherapy, Voceryq, for adults with recurrent respiratory papillomatosis (RRP). This plasmid DNA-based treatment targets HPV-6 and HPV-11, aiming to reduce surgical frequency. The approval is contingent on confirmatory studies, with commercial availability expected in early 2027.